查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1837194

動物治療市場按產品類型、動物類型、給藥途徑、疾病類型、最終用戶和分銷管道分類－全球預測，2025-2032年

Veterinary Therapeutics Market by Product Type, Animal Type, Route Of Administration, Disease Type, End User, Distribution Channel - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 183 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，動物治療市場規模將達到 724.2 億美元，複合年成長率為 7.44%。

關鍵市場統計數據
基準年2024年 407.7億美元
預計年份：2025年 437.5億美元
預測年份 2032 724.2億美元
複合年成長率 (%) 7.44%

一份簡潔的指南，概述了動物療法的範圍、目標和策略意義，面向臨床、商業和監管等各個領域的相關人員。

本執行摘要清晰闡述了動物治療企業面臨的策略和營運要務。透過設定涵蓋產品創新、臨床應用、監管動態、通路和終端用戶工作流程的研究範圍，後續分析得以置於切實可行的決策情境中。明確研究範圍並提出關鍵問題，相關人員可以立即將自身內部優先事項與後續的證據和建議進行配對。

引言部分重點闡述了動物治療領域為何值得經營團隊關注，包括產品系列日益複雜、安全性和有效性預期不斷提高、給藥途徑不斷演變以及整合商業模式日益重要等問題。引言還概述了研究方法，重點介紹如何整合與臨床醫生和行業領袖的訪談、監管分析以及跨職能檢驗研討會。最後，本部分提供了切實可行的見解，並論證了將研究結果納入近期規劃週期的策略價值。

重點分析變革性的技術、監管和經濟變化如何再形成動物保健產業，並推動整個價值鏈的策略調整。

動物治療領域正經歷多重變革的交匯，這些變革正在重塑產品的研發、檢驗和動物應用方式。生技藥品（包括細胞療法、單株抗體和重組蛋白）的進步，拓展了傳統小分子藥物以外的治療選擇。同時，飼料添加劑（如酵素、益生元和益生菌）的創新，正將人們的關注點轉向疾病預防和性能提升干預措施，而新一代殺寄生蟲劑和精準疫苗則正在重新定義疾病管理策略。這些產品層面的轉變正在改變研發週期、監管考量和商業化模式。

監理和商業動態同樣重要。監管機構日益重視藥物安全檢測和真實世界證據，並要求申辦單位建立更完善的上市後監測系統。同時，數位化分銷管道和電子商務正在顛覆傳統供應鏈，重塑與終端用戶的關係。這些趨勢，以及對抗生素管理和合理使用的日益重視，都要求企業採取跨職能協作的方式，將研發、監管事務、市場准入和商業營運有機結合起來。簡而言之，為了實現長期價值，醫藥產業必須適應技術進步、日益嚴格的監管以及不斷變化的客戶期望。

對 2025 年美國累積關稅如何改變動物治療藥物的供應鏈、成本結構和競爭動態進行基於證據的評估。

美國累積關稅將於2025年生效，由此引發了一系列結構性壓力，波及動物治療產品的籌資策略、生產經濟效益和分銷計劃。關稅造成的成本差異迫使企業重新評估其全球供應商網路，並考慮近岸外包或區域生產，以確保利潤率並確保供應的連續性。這種調整也影響產品生命週期管理，因為製造商必須權衡集中生產的效率和多元化區域生產能力的韌性之間的優點和缺點。

從商業性角度來看，關稅政策提高了經銷商、醫院藥局和零售商對成本透明度和合約彈性的重視程度。企業正在透過重新設計商業合約、簽訂多年供應協議以及加強庫存管理來應對，以降低關稅突發變化帶來的風險。對於創新者和小型開發商而言，關稅環境增加了市場決策的複雜性，並影響了合作夥伴的選擇和定價策略。在這種環境下，那些積極重新設計供應鏈並加強與物流和分銷合作夥伴協作的企業，將更有利於在應對利潤壓力的同時，保障動物群體的持續護理。

基於細分市場的洞察，將產品、動物、給藥途徑、疾病、最終用戶和分銷管道的細分轉化為可操作的研發、商業化和服務交付策略。

深度細分洞察揭示了產品類型、動物群體、給藥途徑、疾病類型、終端用戶和分銷管道如何在治療領域創造差異化的機會和挑戰。按產品類型分類，生技藥品（如細胞療法、單株抗體和重組蛋白）需要特殊的低溫運輸物流和監管途徑，這與飼料添加劑（如酵素、益生元和益生菌）顯著不同。殺寄生蟲藥分為體外殺寄生蟲藥和體內殺寄生蟲藥，二者在抗藥性管理上有差異。藥品包括抗發炎藥物、抗生素和激素，每種藥物都有其獨特的管理和處方動態。疫苗則因其不同的安全性特徵和給藥方案而有所區別，包括去活化疫苗、減毒活病毒疫苗疫苗和重組疫苗。

依產品類型進行細分會進一步影響產品設計和服務模式。水產養殖物種，例如甲殼類動物、淡水魚和海水魚，需要專門的給藥系統和環境考量，這與伴侶動物（例如鳥類、犬、貓和囓齒動物）有所不同。家畜物種，例如牛、雞、羊、山羊和豬，則優先考慮擴充性、經濟高效且適用於畜群的干涉措施。腸外給藥方法，例如皮內、肌肉內、靜脈和皮下給藥，需要受過訓練的人員和完善的給藥通訊協定。特定疾病細分，例如行為障礙、感染疾病、代謝性疾病、肌肉骨骼疾病、寄生蟲疾病和生殖障礙，會進一步影響臨床試驗設計和上市後支持需求，從而塑造證據生成策略。最終用戶細分，例如門診服務、線上管道、零售藥局和獸醫診所，會影響購買行為、產品組合和教育需求。分銷管道的選擇，例如直銷、電子商務、醫​​院藥房和零售藥房，決定了物流、利潤結構和客戶覆蓋範圍。整合這些細分維度，可以幫助企業優先考慮投資，客製化資料產生策略，並設計符合各個細分市場細微需求的商業模式。

美洲、歐洲、中東和非洲以及亞太地區需求促進因素、監管差異、物流限制和打入市場策略的區域整合

區域動態對法律規範、供應鏈設計和商業性執行有著深遠的影響，並認知到這些差異對於制定協調一致的策略至關重要。在美洲，管理體制和獸醫實踐模式往往有利於先進療法和完善的低溫運輸基礎設施，而商業管道則由綜合經銷商和專業獸醫醫院網路組成。西半球內部的跨境貿易流動也影響採購決策和物流韌性。雖然西歐部分地區保持著嚴格的藥物安全檢測和漸進式的核准途徑，但該區域內的其他司法管轄區在監管能力和市場進入複雜程度上存在差異，因此需要製定適應性強的市場進入和合規策略。

亞太地區呈現出獨特的動態，包括某些市場對創新平台的快速採用、多樣化的動物生產系統以及對畜牧業應用擴充性的重視。在地化生產能力、部分地區的監管現代化以及電子商務的顯著滲透正在塑造新的市場管道。鑑於這些區域差異，企業必須制定差異化的策略，充分考慮監管差異、物流限制、價格敏感度和分銷管道成熟度。對於尋求在這些地區實現永續成長的企業而言，策略性的區域優先排序，輔以有針對性的夥伴關係和區域性臨床證據計劃，至關重要。

一份簡明的企業格局評估報告，重點介紹領先動物保健公司的策略定位、創新軌跡、合作模式和競爭優勢。

動物治療產業格局複雜多樣，既有成熟的製藥公司，也有專業的生技藥品開發商、契約製造，以及專注於細分市場或平台技術的敏捷型新興企業。大型公司通常利用全球商業網路、強大的藥物安全檢測系統和整合的開發平臺來支持其廣泛的產品系列，而專業公司則專注於高利潤的治療領域，例如單株抗體、細胞療法和重組疫苗平台。受託製造廠商和物流專家發揮關鍵作用，他們能夠實現規模化生產、低溫運輸管理，並建立靈活的生產佈局，以適應關稅主導的供應鏈變化。

夥伴關係、授權協議和策略性收購仍將是產能提升和市場滲透的關鍵機制。創新者與當地經銷商和醫院藥房網路之間的合作能夠加快產品上市速度，並減輕與當地監管機構溝通的負擔。此外，投資於真實世界證據生成、數位化監管和臨床醫生教育的公司，將透過增強信任並證明產品的長期安全性和有效性，從而獲得競爭優勢。在這種環境下，差異化將不再主要取決於產品類別，而是更取決於公司如何整合治療效果、供應可靠性以及為獸醫和動物飼主提供的支援服務。

為幫助產業領導者適應監管變化、關稅影響和不斷變化的臨床需求，同時加速永續成長和增強韌性，提供切實可行的策略建議。

行業領導者應採取一系列切實可行的策略，在保持商業性成長勢頭的同時，應對監管的複雜性、關稅波動以及不斷變化的臨床需求。這些策略包括供應商多元化、評估關鍵零件的近岸外包以及加強庫存管理以應對關稅波動。其次，企業應加快對上市後監測和真實世界證據平台的投資，以滿足日益成長的監管期望，並支持疫苗、生技藥品和高觸感藥物的差異化提案主張。這樣做將有助於加強風險管理，並為採購者和政策制定者提供令人信服的臨床論點。

第三，策略性的商業性調整勢在必行。企業應調整通路策略，根據需要充分利用線上通路和醫院藥局合作關係，同時與門診服務機構和零售商保持緊密聯繫，以確保產品廣泛覆蓋。第四，研發組合的優先排序應基於細分市場標準，並考慮給藥途徑、物種特異性需求和疾病負擔等因素。最後，企業領導者必須在整個生態系統中建立合作夥伴關係，包括與契約製造、物流供應商和區域經銷商的合作，以加速市場准入並管控營運風險。協調一致地落實這些建議，將有助於企業應對短期挑戰，同時為長期價值創造奠定基礎。

調查方法和資料來源的透明度：我們解釋了支撐我們研究結論和相關人員信心的資料來源、分析框架、細分邏輯和品管。

本分析的調查方法結合了定性和定量方法，以確保研究結果的穩健性和可重複性，並為決策提供有力支持。主要研究包括對來自不同地區的臨床醫生、監管專家、供應鏈經理和商業領袖進行結構化訪談，以深入了解實際營運情況。次要研究整合了監管指導文件、臨床文獻和行業報告，以檢驗和闡釋主要研究的趨勢。透過與相關領域專家舉辦交叉檢驗研討會，進行三角驗證，以消除觀點差異並探討策略意義。

此分析架構採用基於產品類型、動物類別、給藥途徑、疾病類型、最終用戶和分銷管道的細分邏輯，以挖掘可操作的差異化因素。品管包括資訊來源檢驗、調查方法審核和情境測試，以評估對關鍵假設（例如關稅調整和監管政策變化）的敏感性。在適用情況下，應用證據等級制度來優先考慮更高品質的臨床和監管資訊來源。這種多層次的調查方法確保了結論得到多元化資訊來源的支持，並建議具有可操作性和說服力。

對各項結論進行簡明扼要的綜合分析，將策略意義、營運重點和投資考量連結起來，形成一個連貫的敘述，供決策者和相關人員參考。

總之，動物治療領域正處於曲折點，其驅動力包括技術創新、不斷變化的監管環境和轉變的商業性模式。那些採用系統觀點，將產品開發、供應鏈設計、監管策略和通路執行有機結合的研發機構，將更有能力將科學進步轉化為持久的市場差異化優勢。先進生技藥品、不斷發展的疫苗平台以及不斷變化的給藥偏好所帶來的綜合影響，要求我們整合證據並積極與相關人員進行有效溝通。

展望未來，韌性和適應性將決定競爭優勢。那些積極應對關稅和物流壓力、主動重塑供應鏈、投資於上市後證據體系、並根據生產線和終端用戶的細微需求客製化產品的公司，將獲得不成比例的巨大價值。最終的成功取決於嚴謹的優先順序、策略夥伴關係關係，以及將研究成果轉化為能夠改善臨床療效並維持商業性績效的營運方案的能力。這種整合應成為決策者制定短期和中期行動計畫的策略指南。

目錄

第1章：序言

第2章調查方法

第3章執行摘要

第4章 市場概覽

第5章 市場洞察

  • 將人工智慧融入診斷影像技術，以增強獸醫疾病的檢測和治療方案的發展。
  • 針對伴侶動物慢性發炎疾病的物種特異性單株抗體療法的研發
  • 新型抗菌肽的出現可對抗家畜群體中的多重抗藥性細菌感染疾病
  • 基因編輯技術（例如 CRISPR）在治療馬和牛的遺傳疾病方面的進步
  • 提高小動物疼痛管理中長效注射劑的監管核准
  • 支持老年寵物關節健康和活動能力的營養補充劑和機能性食品市場成長
  • 利用物聯網設備和高級分析技術，在酪農快速實施數據驅動的畜群健康計劃

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：依產品類型分類的動物治療市場

  • 生物製藥
    • 細胞療法
    • 單株抗體
    • 重組蛋白
  • 飼料添加劑
    • 酵素
    • 益生元
    • 益生菌
  • 殺寄生蟲劑
    • 體外寄生蟲殺滅劑
    • Endectocides
  • 製藥
    • 抗發炎藥
    • 抗生素
    • 荷爾蒙
  • 疫苗
    • 惰性
    • 減毒活病毒疫苗
    • 重組

第9章：以動物類型分類的動物治療市場

  • 水產養殖
    • 甲殼類動物
    • 淡水魚
    • 海水魚
  • 伴侶動物
    • 鳥類
    • 狗
    • 貓
    • 囓齒動物
  • 馬
    • 馬術
    • 賽馬
    • 休閒馬匹
  • 家畜
    • 牛
    • 家禽
    • 綿羊和山羊
    • 豬

第10章：依給藥途徑分類的動物治療藥物市場

  • 吸入
  • 口服
  • 腸外
    • 皮內注射
    • 肌肉注射
    • 靜脈
    • 皮下
  • 外用

第11章：依疾病類型分類的動物治療市場

  • 行為障礙
  • 感染疾病
  • 代謝紊亂
  • 肌肉骨骼疾病
  • 寄生蟲病
  • 生殖障礙

第12章：按最終用戶分類的動物治療市場

  • 門診服務
  • 線上管道
  • 零售藥房
  • 獸醫診所

第13章：按通路分類的動物治療市場

  • 直銷
  • 電子商務
  • 醫院藥房
  • 零售藥房

第14章：按地區分類的動物治療市場

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第15章 按群體分類的動物治療市場

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第16章：各國動物治療藥物市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第17章 競爭格局

  • 2024年市佔率分析
  • FPNV定位矩陣，2024
  • 競爭分析
    • Zoetis Inc.
    • Merck & Co., Inc.
    • Boehringer Ingelheim International GmbH
    • Elanco Animal Health Incorporated
    • Bayer Aktiengesellschaft
    • Ceva Sante Animale SA
    • Virbac SA
    • Vetoquinol SA
    • Dechra Pharmaceuticals PLC
    • Phibro Animal Health Corporation
Product Code: MRR-034B500303A2

The Veterinary Therapeutics Market is projected to grow by USD 72.42 billion at a CAGR of 7.44% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 40.77 billion
Estimated Year [2025] USD 43.75 billion
Forecast Year [2032] USD 72.42 billion
CAGR (%) 7.44%

A concise orientation that outlines the scope, objectives, and strategic relevance of veterinary therapeutics to stakeholders across clinical, commercial, and regulatory domains

This executive summary opens with a clear orientation that frames the strategic and operational imperatives facing organizations engaged in veterinary therapeutics. It establishes the scope of inquiry across product innovation, clinical application, regulatory dynamics, distribution pathways, and end-user workflows, thereby situating subsequent analysis within a pragmatic decision-making context. By defining the boundaries of the research and articulating the primary questions addressed, stakeholders can immediately align internal priorities with the evidence and recommendations that follow.

The introduction emphasizes why veterinary therapeutics warrants heightened executive attention: rising complexity in product portfolios, accelerating expectations for safety and efficacy, evolving routes of administration, and the growing importance of integrated commercial models. It also outlines the methodological approach at a high level, highlighting the synthesis of primary interviews with clinicians and industry leaders, secondary regulatory analysis, and cross-functional validation workshops. Ultimately, this opening section sets expectations for actionable insights and signals the strategic value of integrating research findings into near-term planning cycles.

A focused analysis of transformative technological, regulatory, and economic shifts reshaping veterinary therapeutics and driving strategic realignment across the value chain

The veterinary therapeutics landscape is undergoing several convergent transformations that are reconfiguring how products are developed, validated, and delivered to animal populations. Advances in biologics, including cell therapies, monoclonal antibodies, and recombinant proteins, are expanding therapeutic options beyond traditional small-molecule pharmaceuticals. Concurrently, innovation in feed additives such as enzymes, prebiotics, and probiotics is shifting attention toward preventive and performance-enhancing interventions, while next-generation parasiticides and precision vaccines are redefining disease control strategies. These product-level shifts are altering development timelines, regulatory considerations, and commercialization models.

Equally important are regulatory and commercial dynamics. Regulatory authorities are increasingly emphasizing pharmacovigilance and real-world evidence, prompting sponsors to build stronger post-market surveillance infrastructures. At the same time, digital distribution channels and e-commerce are disrupting conventional supply chains and reshaping interactions with end users. Together with greater emphasis on antimicrobial stewardship and responsible use, these trends require companies to adopt cross-functional approaches that bridge R&D, regulatory affairs, market access, and commercial operations. In short, the industry must adapt to technological progress, heightened oversight, and changing customer expectations to capture long-term value.

An evidence-based appraisal of how the cumulative United States tariffs enacted in 2025 are altering supply chains, cost structures, and competitive dynamics in veterinary therapeutics

The cumulative implementation of United States tariffs in 2025 introduced a set of structural pressures that ripple across sourcing strategies, manufacturing economics, and distribution planning for veterinary therapeutics. Tariff-induced cost differentials have compelled organizations to re-evaluate global supplier networks and to consider nearshoring or regional manufacturing to preserve margin and ensure supply continuity. This recalibration has implications for product lifecycle management, as manufacturers must weigh the trade-offs between centralized production efficiencies and the resilience offered by diversified regional capacity.

From a commercial standpoint, tariffs have elevated the importance of cost transparency and contract flexibility among distributors, hospital pharmacies, and retail partners. Companies are responding by redesigning commercial agreements, securing multi-year supplier commitments, and enhancing inventory management practices to mitigate exposure to sudden duty changes. For innovators and smaller developers, the tariff environment has increased the complexity of market entry decisions, influencing partner selection and pricing strategies. In this environment, organizations that proactively redesign their supply chains and strengthen collaborative relationships with logistics providers and distribution partners will be better positioned to maintain continuity of care for animal populations while managing margin pressure.

Segment-driven insights that translate product, animal, administration, disease, end-user, and distribution segmentations into practical implications for R&D, commercialization, and service delivery

Deep segmentation insight reveals how distinct product categories, animal populations, administration routes, disease types, end users, and distribution channels create differentiated opportunities and constraints across the therapeutic landscape. Product-wise, biologics such as cell therapies, monoclonal antibodies, and recombinant proteins demand specialized cold-chain logistics and regulatory pathways that differ markedly from feed additives like enzymes, prebiotics, and probiotics, which focus on preventive benefits and on-farm integration. Parasiticides split into ectoparasiticides and endectocides with divergent resistance management needs, while pharmaceuticals encompass anti-inflammatories, antibiotics, and hormones that each have unique stewardship and prescription dynamics. Vaccines present another axis of differentiation where inactivated, live attenuated, and recombinant platforms carry distinct safety profiles and administration protocols.

Animal-type segmentation further shapes product design and service models. Aquaculture modalities such as crustaceans, freshwater fish, and marine fish require specialized delivery systems and environmental considerations that differ from companion animals like avian, canine, feline, and rodents, which demand high-touch clinical interfaces and owner-focused communication. Equine populations-performance horses, racing horses, and recreational horses-present heterogenous therapeutic priorities tied to performance, regulatory testing, and owner investment, whereas livestock segments such as cattle, poultry, sheep and goats, and swine prioritize scalability, cost-efficiency, and herd-level interventions. Route of administration also maps to both product development and user preference: inhalation and oral options facilitate ease of use for certain species, while parenteral approaches, including intradermal, intramuscular, intravenous, and subcutaneous methods, require trained personnel and robust delivery protocols. Disease-type segmentation-behavioral disorders, infectious diseases, metabolic disorders, musculoskeletal disorders, parasitic diseases, and reproductive disorders-further informs clinical trial design and post-market support needs, shaping evidence generation strategies. End-user distinctions across ambulatory services, online channels, retail pharmacies, and veterinary hospitals influence purchasing behavior, product bundling, and educational requirements, and distribution channel choices between direct sales, e-commerce, hospital pharmacies, and retail pharmacies determine logistics, margin structures, and customer reach. By integrating these segmentation dimensions, companies can prioritize investments, tailor evidence generation, and design commercial models that align with the nuanced needs of each market niche.

A regional synthesis of demand drivers, regulatory divergence, logistical constraints, and market access strategies across the Americas, Europe, Middle East & Africa, and Asia-Pacific

Regional dynamics exert a powerful influence on regulatory frameworks, supply chain design, and commercial execution, and recognizing these distinctions is essential for coherent strategy. In the Americas, regulatory regimes and veterinary practice patterns tend to favor advanced therapeutics and robust cold-chain infrastructure, while commercial channels exhibit a blend of consolidated distributors and specialized veterinary hospital networks. Cross-border trade flows within the hemisphere also shape sourcing decisions and logistics resilience. Moving across to Europe, Middle East & Africa, regulatory heterogeneity becomes a defining characteristic: while parts of Western Europe maintain stringent pharmacovigilance and progressive approval pathways, other jurisdictions within the broader region present varying levels of regulatory capacity and market access complexity, requiring adaptable market entry and compliance strategies.

The Asia-Pacific region brings its own set of dynamics, including rapid adoption of innovative platforms in certain markets, diverse animal production systems, and a strong emphasis on scalability for livestock applications. Local manufacturing capabilities, regulatory modernization in some jurisdictions, and significant e-commerce penetration are shaping new routes to market. Given these regional contrasts, companies must design differentiated approaches that account for regulatory divergence, logistics constraints, pricing sensitivity, and distribution channel maturity. Strategic regional prioritization, supported by targeted partnerships and localized clinical evidence plans, will be instrumental for organizations seeking sustainable growth across these geographies.

A concise corporate landscape assessment highlighting strategic positioning, innovation trajectories, partnership patterns, and competitive differentiators across leading veterinary therapeutics firms

The corporate landscape in veterinary therapeutics reflects a mix of established pharmaceutical firms, specialized biologics developers, contract manufacturers, and agile startups that focus on niche segments or platform technologies. Larger firms typically leverage global commercial networks, robust pharmacovigilance systems, and integrated R&D pipelines to support broad product portfolios, whereas specialized companies concentrate on high-margin therapeutic niches such as monoclonal antibodies, cell therapies, or recombinant vaccine platforms. Contract manufacturing organizations and logistics specialists play a critical role by enabling scale-up, cold-chain management, and flexible production footprints that can respond to tariff-driven supply chain shifts.

Partnerships, licensing agreements, and strategic acquisitions continue to be primary mechanisms for capability development and market entry. Collaboration between innovators and regional distributors or hospital pharmacy networks accelerates access while reducing the burden of local regulatory navigation. Moreover, companies that invest in real-world evidence generation, digital surveillance, and clinician education secure competitive advantages by strengthening trust and demonstrating long-term safety and efficacy. In this environment, differentiation derives less from basic product classes and more from how firms orchestrate integrated solutions that combine therapeutic efficacy, supply reliability, and support services for veterinarians and animal owners.

Actionable strategic recommendations that equip industry leaders to adapt to regulatory changes, tariff impacts, and evolving clinical needs while accelerating sustainable growth and resilience

Industry leaders should adopt a set of pragmatic strategies to address regulatory complexity, tariff disruption, and evolving clinical needs while preserving commercial momentum. First, organizations must redesign supply chain architectures to prioritize resilience; this includes diversifying supplier bases, evaluating nearshoring for critical components, and strengthening inventory controls to buffer against tariff volatility. Second, companies should accelerate investments in post-market surveillance and real-world evidence platforms to meet heightened regulatory expectations and to support differentiated value propositions for vaccines, biologics, and high-touch pharmaceuticals. By doing so, they will enhance risk management and provide compelling clinical narratives to purchasers and policy makers.

Third, strategic commercial realignment is necessary: firms should recalibrate channel strategies to leverage online channels and hospital pharmacy partnerships where appropriate while maintaining strong relationships with ambulatory services and retail outlets for broad access. Fourth, R&D portfolios ought to be prioritized using segmentation-informed criteria that consider route of administration, species-specific needs, and disease burden; focusing resources on platforms with clear clinical and logistical advantages will improve return on development effort. Finally, leaders must cultivate collaborative partnerships across the ecosystem, including contract manufacturers, logistics providers, and regional distributors, to accelerate market entry and manage operational risk. Implementing these recommendations in a coordinated manner will help organizations navigate near-term headwinds while positioning for long-term value creation.

Methodological transparency describing data sources, analytical frameworks, segmentation logic, and quality controls that underpin the research conclusions and stakeholder confidence

The research methodology underpinning this analysis combines qualitative and quantitative approaches to ensure robust, reproducible findings and to support confident decision making. Primary research included structured interviews with clinicians, regulatory experts, supply chain managers, and commercial leaders across varied geographies to capture real-world operational insights. Secondary research integrated regulatory guidance documents, clinical literature, and industry reports to validate trends and contextualize primary findings. Triangulation occurred through cross-validation workshops with subject matter experts to reconcile divergent views and to refine implications for strategy.

Analytical frameworks employed segmentation logic across product types, animal categories, routes of administration, disease types, end users, and distribution channels to surface actionable differentiation. Quality controls included source verification, methodological audits, and scenario testing to assess sensitivity to key assumptions such as tariff shifts and regulatory policy changes. Wherever applicable, evidence hierarchies were applied to prioritize higher-quality clinical and regulatory sources. This layered methodological approach ensures that conclusions are grounded in diverse evidence streams and that recommendations are both pragmatic and defensible.

A succinct concluding synthesis that ties strategic implications, operational priorities, and investment considerations into a coherent narrative for decision makers and stakeholders

In conclusion, the veterinary therapeutics sector stands at an inflection point driven by technological innovation, regulatory evolution, and shifting commercial architectures. Organizations that adopt a systems perspective-aligning product development, supply chain design, regulatory strategy, and channel execution-will be better equipped to convert scientific advances into durable market differentiation. The combined effects of advanced biologics, evolving vaccine platforms, and changing administration preferences necessitate integrated evidence generation and robust stakeholder engagement.

Looking ahead, resilience and adaptability will define competitive advantage. Firms that proactively redesign supply networks in response to tariff and logistical pressures, invest in post-market evidence systems, and tailor offerings to the nuanced needs of species and end users will capture disproportionate value. Ultimately, success will depend on disciplined prioritization, strategic partnerships, and the ability to translate research into operational programs that improve clinical outcomes and sustain commercial performance. This synthesis should serve as a strategic compass for decision makers planning near- and medium-term actions.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Integration of artificial intelligence in diagnostic imaging to enhance veterinary disease detection and treatment planning
  • 5.2. Development of species-specific monoclonal antibody therapies targeting chronic inflammatory conditions in companion animals
  • 5.3. Emergence of novel antimicrobial peptides to combat multidrug-resistant bacterial infections in livestock populations
  • 5.4. Advancement of gene editing technologies such as CRISPR for treatment of hereditary diseases in equine and bovine patients
  • 5.5. Increasing regulatory approval of long-acting injectable formulations for pain management in small animal practice
  • 5.6. Growth of nutraceutical and functional food products to support joint health and mobility in aging companion animals
  • 5.7. Rapid implementation of data-driven herd health programs leveraging IoT devices and advanced analytics in dairy farms

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Veterinary Therapeutics Market, by Product Type

  • 8.1. Biologics
    • 8.1.1. Cell Therapies
    • 8.1.2. Monoclonal Antibodies
    • 8.1.3. Recombinant Proteins
  • 8.2. Feed Additives
    • 8.2.1. Enzymes
    • 8.2.2. Prebiotics
    • 8.2.3. Probiotics
  • 8.3. Parasiticides
    • 8.3.1. Ectoparasiticides
    • 8.3.2. Endectocides
  • 8.4. Pharmaceuticals
    • 8.4.1. Anti-Inflammatories
    • 8.4.2. Antibiotics
    • 8.4.3. Hormones
  • 8.5. Vaccines
    • 8.5.1. Inactivated
    • 8.5.2. Live Attenuated
    • 8.5.3. Recombinant

9. Veterinary Therapeutics Market, by Animal Type

  • 9.1. Aquaculture
    • 9.1.1. Crustaceans
    • 9.1.2. Freshwater Fish
    • 9.1.3. Marine Fish
  • 9.2. Companion Animals
    • 9.2.1. Avian
    • 9.2.2. Canine
    • 9.2.3. Feline
    • 9.2.4. Rodents
  • 9.3. Equine
    • 9.3.1. Performance Horses
    • 9.3.2. Racing Horses
    • 9.3.3. Recreational Horses
  • 9.4. Livestock
    • 9.4.1. Cattle
    • 9.4.2. Poultry
    • 9.4.3. Sheep & Goats
    • 9.4.4. Swine

10. Veterinary Therapeutics Market, by Route Of Administration

  • 10.1. Inhalation
  • 10.2. Oral
  • 10.3. Parenteral
    • 10.3.1. Intradermal
    • 10.3.2. Intramuscular
    • 10.3.3. Intravenous
    • 10.3.4. Subcutaneous
  • 10.4. Topical

11. Veterinary Therapeutics Market, by Disease Type

  • 11.1. Behavioral Disorders
  • 11.2. Infectious Diseases
  • 11.3. Metabolic Disorders
  • 11.4. Musculoskeletal Disorders
  • 11.5. Parasitic Diseases
  • 11.6. Reproductive Disorders

12. Veterinary Therapeutics Market, by End User

  • 12.1. Ambulatory Services
  • 12.2. Online Channels
  • 12.3. Retail Pharmacies
  • 12.4. Veterinary Hospitals

13. Veterinary Therapeutics Market, by Distribution Channel

  • 13.1. Direct Sales
  • 13.2. E-Commerce
  • 13.3. Hospital Pharmacies
  • 13.4. Retail Pharmacies

14. Veterinary Therapeutics Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Veterinary Therapeutics Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Veterinary Therapeutics Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. Competitive Landscape

  • 17.1. Market Share Analysis, 2024
  • 17.2. FPNV Positioning Matrix, 2024
  • 17.3. Competitive Analysis
    • 17.3.1. Zoetis Inc.
    • 17.3.2. Merck & Co., Inc.
    • 17.3.3. Boehringer Ingelheim International GmbH
    • 17.3.4. Elanco Animal Health Incorporated
    • 17.3.5. Bayer Aktiengesellschaft
    • 17.3.6. Ceva Sante Animale S.A.
    • 17.3.7. Virbac S.A.
    • 17.3.8. Vetoquinol S.A.
    • 17.3.9. Dechra Pharmaceuticals PLC
    • 17.3.10. Phibro Animal Health Corporation

LIST OF FIGURES

  • FIGURE 1. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY ANIMAL TYPE, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY ANIMAL TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
  • FIGURE 13. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. AMERICAS VETERINARY THERAPEUTICS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. NORTH AMERICA VETERINARY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. LATIN AMERICA VETERINARY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA VETERINARY THERAPEUTICS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. EUROPE VETERINARY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. MIDDLE EAST VETERINARY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. AFRICA VETERINARY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASIA-PACIFIC VETERINARY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. ASEAN VETERINARY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. GCC VETERINARY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. EUROPEAN UNION VETERINARY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. BRICS VETERINARY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. G7 VETERINARY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. NATO VETERINARY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 30. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 31. VETERINARY THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 32. VETERINARY THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. VETERINARY THERAPEUTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY BIOLOGICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY BIOLOGICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY BIOLOGICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY BIOLOGICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY BIOLOGICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY BIOLOGICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY CELL THERAPIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY CELL THERAPIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY CELL THERAPIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY CELL THERAPIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY CELL THERAPIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY CELL THERAPIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY RECOMBINANT PROTEINS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY RECOMBINANT PROTEINS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY RECOMBINANT PROTEINS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY RECOMBINANT PROTEINS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY RECOMBINANT PROTEINS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY RECOMBINANT PROTEINS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY FEED ADDITIVES, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY FEED ADDITIVES, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY FEED ADDITIVES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY FEED ADDITIVES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY FEED ADDITIVES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY FEED ADDITIVES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY FEED ADDITIVES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY FEED ADDITIVES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY ENZYMES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY ENZYMES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY ENZYMES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY ENZYMES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY ENZYMES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY ENZYMES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY PREBIOTICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY PREBIOTICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY PREBIOTICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY PREBIOTICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY PREBIOTICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY PREBIOTICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY PROBIOTICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY PROBIOTICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY PROBIOTICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY PROBIOTICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY PROBIOTICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY PROBIOTICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY PARASITICIDES, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY PARASITICIDES, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY PARASITICIDES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY PARASITICIDES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY PARASITICIDES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY PARASITICIDES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY PARASITICIDES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY PARASITICIDES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY ECTOPARASITICIDES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY ECTOPARASITICIDES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY ECTOPARASITICIDES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY ECTOPARASITICIDES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY ECTOPARASITICIDES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY ECTOPARASITICIDES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY ENDECTOCIDES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY ENDECTOCIDES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY ENDECTOCIDES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY ENDECTOCIDES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY ENDECTOCIDES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY ENDECTOCIDES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY PHARMACEUTICALS, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY PHARMACEUTICALS, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY PHARMACEUTICALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY PHARMACEUTICALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY PHARMACEUTICALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY PHARMACEUTICALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY PHARMACEUTICALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY PHARMACEUTICALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY ANTI-INFLAMMATORIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY ANTI-INFLAMMATORIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY ANTI-INFLAMMATORIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY ANTI-INFLAMMATORIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY ANTI-INFLAMMATORIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY ANTI-INFLAMMATORIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY HORMONES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY HORMONES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY HORMONES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY HORMONES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY HORMONES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY HORMONES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY VACCINES, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY VACCINES, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY VACCINES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY VACCINES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY VACCINES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY VACCINES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY VACCINES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY VACCINES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY INACTIVATED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY INACTIVATED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY INACTIVATED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY INACTIVATED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY INACTIVATED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY INACTIVATED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY LIVE ATTENUATED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY LIVE ATTENUATED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY LIVE ATTENUATED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY LIVE ATTENUATED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY LIVE ATTENUATED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY LIVE ATTENUATED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY RECOMBINANT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY RECOMBINANT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY RECOMBINANT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY RECOMBINANT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY RECOMBINANT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY RECOMBINANT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY ANIMAL TYPE, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY ANIMAL TYPE, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY AQUACULTURE, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY AQUACULTURE, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY AQUACULTURE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY AQUACULTURE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY AQUACULTURE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY AQUACULTURE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY AQUACULTURE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY AQUACULTURE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY CRUSTACEANS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY CRUSTACEANS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY CRUSTACEANS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY CRUSTACEANS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY CRUSTACEANS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY CRUSTACEANS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY FRESHWATER FISH, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY FRESHWATER FISH, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY FRESHWATER FISH, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY FRESHWATER FISH, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY FRESHWATER FISH, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY FRESHWATER FISH, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY MARINE FISH, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY MARINE FISH, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY MARINE FISH, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY MARINE FISH, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY MARINE FISH, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY MARINE FISH, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY COMPANION ANIMALS, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY COMPANION ANIMALS, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY COMPANION ANIMALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY COMPANION ANIMALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY COMPANION ANIMALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY COMPANION ANIMALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY COMPANION ANIMALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY COMPANION ANIMALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY AVIAN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY AVIAN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY AVIAN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY AVIAN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY AVIAN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY AVIAN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY CANINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY CANINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY CANINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY CANINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY CANINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY CANINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY FELINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY FELINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY FELINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY FELINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY FELINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY FELINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY RODENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY RODENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY RODENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY RODENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY RODENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY RODENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY EQUINE, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY EQUINE, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY EQUINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY EQUINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY EQUINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY EQUINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY EQUINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY EQUINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY PERFORMANCE HORSES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY PERFORMANCE HORSES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY PERFORMANCE HORSES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY PERFORMANCE HORSES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY PERFORMANCE HORSES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY PERFORMANCE HORSES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY RACING HORSES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY RACING HORSES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY RACING HORSES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY RACING HORSES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY RACING HORSES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY RACING HORSES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY RECREATIONAL HORSES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY RECREATIONAL HORSES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY RECREATIONAL HORSES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY RECREATIONAL HORSES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY RECREATIONAL HORSES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY RECREATIONAL HORSES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 217. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY LIVESTOCK, 2018-2024 (USD MILLION)
  • TABLE 218. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY LIVESTOCK, 2025-2032 (USD MILLION)
  • TABLE 219. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY LIVESTOCK, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 220. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY LIVESTOCK, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 221. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY LIVESTOCK, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 222. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY LIVESTOCK, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 223. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY LIVESTOCK, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 224. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY LIVESTOCK, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 225. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY CATTLE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 226. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY CATTLE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 227. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY CATTLE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 228. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY CATTLE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 229. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY CATTLE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 230. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY CATTLE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 231. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY POULTRY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 232. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY POULTRY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 233. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY POULTRY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 234. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY POULTRY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 235. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY POULTRY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 236. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY POULTRY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 237. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY SHEEP & GOATS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 238. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY SHEEP & GOATS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 239. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY SHEEP & GOATS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 240. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY SHEEP & GOATS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 241. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY SHEEP & GOATS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 242. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY SHEEP & GOATS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 243. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY SWINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 244. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY SWINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 245. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY SWINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 246. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY SWINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 247. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY SWINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 248. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY SWINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 249. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 250. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 251. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY INHALATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 252. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY INHALATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 253. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY INHALATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 254. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY INHALATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 255. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY INHALATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 256. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY INHALATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 257. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 258. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY ORAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 259. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY ORAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 260. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY ORAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 261. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 262. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY ORAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 263. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2024 (USD MILLION)
  • TABLE 264. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2025-2032 (USD MILLION)
  • TABLE 265. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY PARENTERAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 266. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY PARENTERAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 267. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY PARENTERAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 268. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY PARENTERAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 269. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY PARENTERAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 270. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY PARENTERAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 271. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY INTRADERMAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 272. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY INTRADERMAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 273. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY INTRADERMAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 274. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY INTRADERMAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 275. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY INTRADERMAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 276. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY INTRADERMAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 277. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 278. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 279. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY INTRAMUSCULAR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 280. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY INTRAMUSCULAR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 281. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY INTRAMUSCULAR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 282. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY INTRAMUSCULAR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 283. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 284. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 285. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 286. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 287. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 288. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 289. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 290. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 291. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 292. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 293. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 294. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 295. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY TOPICAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 296. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY TOPICAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 297. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY TOPICAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 298. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY TOPICAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 299. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY TOPICAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 300. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY TOPICAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 301. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
  • TABLE 302. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2025-2032 (USD MILLION)
  • TABLE 303. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY BEHAVIORAL DISORDERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 304. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY BEHAVIORAL DISORDERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 305. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY BEHAVIORAL DISORDERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 306. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY BEHAVIORAL DISORDERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 307. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY BEHAVIORAL DISORDERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 308. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY BEHAVIORAL DISORDERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 309. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 310. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 311. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY INFECTIOUS DISEASES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 312. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY INFECTIOUS DISEASES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 313. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY